NO and hepatocellular cancer.

Apoptosis Carcinoma, Hepatocellular / drug therapy Cell Line, Tumor Cell Movement Cell Proliferation Gene Expression Regulation, Neoplastic Humans Liver Neoplasms / drug therapy Neoplastic Stem Cells Neovascularization, Pathologic

Journal

British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536

Informations de publication

Date de publication:
12 2020
Historique:
received: 25 02 2019
revised: 26 06 2019
accepted: 01 07 2019
pubmed: 20 8 2019
medline: 22 6 2021
entrez: 20 8 2019
Statut: ppublish

Résumé

NO has broad and sometimes dichotomous roles in cancer. The effects of NO in tumours depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular carcinoma (HCC) is a common and lethal disease for which no effective therapy other than surgical resection exists. Over two decades of research has yielded evidence that NO generated by the inducible NOS (iNOS or NOS2) contributes to HCC progression in at least a subset of patients with HCC. The co-expression of iNOS with COX-2 may portend a particularly aggressive cancer phenotype in HCC and at the same time reveal an opportunity for pharmacological intervention. In this review, we focus on what is known about the influence of NO in HCC neoplastic transformation, proliferation and apoptosis, angiogenesis, invasion, and metastasis, cancer stem cells, and the host immune response against the tumour. We discuss the implications of recent findings for targeting the NO pathways in HCC.

Identifiants

DOI: 10.1111/bph.14838 PMID: 31423564 PMC: PMC7707086
pubmed: 31423564
doi: 10.1111/bph.14838
pmc: PMC7707086
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

5459-5466

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : National Science Foundation of China
ID : 81802418

Informations de copyright

© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Références

J Viral Hepat. 2001 Jan;8(1):63-9
pubmed: 11155153
Cancer Res. 2006 Mar 1;66(5):2673-82
pubmed: 16510587
Cancer Chemother Pharmacol. 2016 Mar;77(3):549-58
pubmed: 26811179
Crit Care Med. 2004 Jan;32(1):13-20
pubmed: 14707555
Curr Opin Genet Dev. 2003 Feb;13(1):28-33
pubmed: 12573432
Cancer Lett. 2014 Oct 10;353(1):1-7
pubmed: 25079686
Carcinogenesis. 2008 Aug;29(8):1639-47
pubmed: 18579559
Lancet Oncol. 2001 Mar;2(3):149-56
pubmed: 11902565
J Surg Res. 1997 May;69(2):321-4
pubmed: 9224400
Lancet. 2003 Dec 6;362(9399):1907-17
pubmed: 14667750
Cancer Treat Res. 2003;115:169-87
pubmed: 12613197
Osteoarthritis Cartilage. 2002 Oct;10(10):792-8
pubmed: 12359165
Cancer Res. 2013 Nov 1;73(21):6526-37
pubmed: 24008318
Curr Mol Med. 2003 Sep;3(6):519-26
pubmed: 14527083
Clin Cancer Res. 2001 May;7(5):1325-32
pubmed: 11350902
Eur Heart J. 2007 May;28(9):1109-16
pubmed: 17459901
Ann Rheum Dis. 2013 Feb;72(2):187-95
pubmed: 23144445
J Carcinog. 2011;10:40
pubmed: 22368515
Hepatology. 2010 Aug;52(2):480-92
pubmed: 20683948
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8823-8
pubmed: 9671763
Lancet. 2000 Jul 22;356(9226):346
pubmed: 11071225
Cancer Cell. 2009 Jun 2;15(6):501-13
pubmed: 19477429
Br J Pharmacol. 2002 Sep;137(1):62-8
pubmed: 12183331
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4671-6
pubmed: 19261856
Redox Biol. 2015 Dec;6:334-343
pubmed: 26335399
Cell. 2011 Jul 8;146(1):53-66
pubmed: 21729780
Angiogenesis. 2017 Nov;20(4):557-565
pubmed: 28741166
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Cancer Res. 2014 Jun 1;74(11):2999-3010
pubmed: 24710408
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8758-63
pubmed: 15939886
FASEB J. 2003 Jul;17(10):1298-300
pubmed: 12738811
Redox Biol. 2015 Aug;5:418
pubmed: 28162283
Gastroenterology. 2004 Nov;127(5 Suppl 1):S218-24
pubmed: 15508087
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9265-9
pubmed: 2827174
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3491-5
pubmed: 7682706
Oncol Lett. 2017 Jun;13(6):4776-4784
pubmed: 28599479
Nat Immunol. 2016 Jun;17(6):656-65
pubmed: 27043409
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359
pubmed: 29055034
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Breast Cancer Res. 2015 Feb 22;17:25
pubmed: 25849745
Acta Physiol Scand. 2003 Oct;179(2):123-35
pubmed: 14510775
Antioxid Redox Signal. 2017 Jun 10;26(17):963-965
pubmed: 28506076
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10127-E10136
pubmed: 30297396
Biochemistry (Mosc). 2000 Apr;65(4):409-26
pubmed: 10810177
J Biol Chem. 2012 Oct 19;287(43):35887-98
pubmed: 22898814
Br J Pharmacol. 2020 Dec;177(24):5459-5466
pubmed: 31423564
Nat Med. 1998 Dec;4(12):1371-6
pubmed: 9846573
Nat Rev Cancer. 2006 Jul;6(7):521-34
pubmed: 16794635
Clin Cancer Res. 2001 Nov;7(11):3385-92
pubmed: 11705852
Cancer Res. 2006 Jul 15;66(14):7024-31
pubmed: 16849547
Curr Cancer Drug Targets. 2009 Mar;9(2):214-36
pubmed: 19275761
Nature. 1980 Nov 27;288(5789):373-6
pubmed: 6253831
J Exp Med. 1992 Jul 1;176(1):261-4
pubmed: 1377225
J Mol Med (Berl). 2019 Feb;97(2):243-255
pubmed: 30564864
Invest New Drugs. 2013 Feb;31(1):99-107
pubmed: 22426640
Oncotarget. 2016 Feb 2;7(5):5754-68
pubmed: 26735577
Cancer Sci. 2019 Mar;110(3):1054-1063
pubmed: 30657629
Am J Cancer Res. 2018 Feb 01;8(2):302-316
pubmed: 29511600
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2442-7
pubmed: 8637893
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):522-6
pubmed: 7678458
Nature. 1987 Jun 11-17;327(6122):524-6
pubmed: 3495737
World J Gastroenterol. 2005 Oct 14;11(38):5931-7
pubmed: 16273602
J Med Chem. 2011 May 12;54(9):3251-9
pubmed: 21504204
Sci Signal. 2015 Jan 27;8(361):ra11
pubmed: 25628461
Nat Rev Cancer. 2003 Apr;3(4):276-85
pubmed: 12671666
Cell. 2004 Feb 20;116(4):617-28
pubmed: 14980227
Clin Chim Acta. 2000 Jun;296(1-2):181-91
pubmed: 10807981
Science. 1987 Jan 23;235(4787):473-6
pubmed: 2432665
Carcinogenesis. 2013 Mar;34(3):503-12
pubmed: 23354310
Am J Gastroenterol. 1997 Sep;92(9):1520-3
pubmed: 9317076
J Clin Oncol. 2004 May 15;22(10):1815-22
pubmed: 15143074
Clin Exp Metastasis. 2003;20(5):445-50
pubmed: 14524534
Shock. 2003 Feb;19(2):117-22
pubmed: 12578118
Carcinogenesis. 1998 May;19(5):711-21
pubmed: 9635855
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):13030-13035
pubmed: 29087320
Oncotarget. 2016 Feb 23;7(8):9525-37
pubmed: 26848615

Auteurs

Ronghua Wang (R)

Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

David A Geller (DA)

Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

David A Wink (DA)

Cancer Inflammation Program, NCI/NIH, Frederick, MD, USA.
ORCID: 0000-0002-5652-7480

Bin Cheng (B)

Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Timothy R Billiar (TR)

Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
ORCID: 0000-0002-2949-0811

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › NO and hepatocellular cancer.
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › NO and hepatocellular cancer.
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › NO and hepatocellular cancer.
questionsmedicales.fr › Phénomènes physiologiques › Mouvement cellulaire › NO and hepatocellular cancer.
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › NO and hepatocellular cancer.
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › NO and hepatocellular cancer.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › NO and hepatocellular cancer.
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › NO and hepatocellular cancer.
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches tumorales › NO and hepatocellular cancer.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Métaplasie › Néovascularisation pathologique › NO and hepatocellular cancer.